Patents Assigned to National University Corporation University of Toyama
-
Patent number: 11970549Abstract: The invention provides an antibody that specifically binds to a 5? to 3? exonuclease domain of a DNA polymerase, or a fragment thereof. The antibody inhibits the 5? to 3? exonuclease activity of a DNA polymerase, or a fragment thereof.Type: GrantFiled: December 10, 2021Date of Patent: April 30, 2024Assignees: TOYOBO CO., LTD., NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMAInventors: Takafumi Yoshikane, Nobuyuki Kurosawa, Masaharu Isobe
-
Publication number: 20240041497Abstract: To ensure that a biodegradable medical implement dissolves in vivo at an appropriate dissolution rate. The biodegradable medical implement of the present invention is formed of a magnesium material, and, at least in one transverse section, a layer of magnesium crystal grains in which a (0001) plane in a hexagonal crystal structure is oriented toward a surface side is continuous over an entire circumference.Type: ApplicationFiled: November 29, 2021Publication date: February 8, 2024Applicants: NITTO SEIKO CO., LTD., KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION, NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMAInventors: Masakazu Ishihara, Yoshimitsu Ueno, Tomoaki Murata, Yukito Otsuki, Yusuke Kobayashi, Yoshinobu Oka, Wook-Cheol Kim, Tetsuo Aida, Sadami Tsutsumi
-
Patent number: 11655273Abstract: Provided are a ligand-bearing substrate which has a surface at least partially coated with a polymer (P3) containing structural units represented by the formulae (1a) and (1b) (in the formulae, R1, R2, X, Y, L, Q1, Q2, Q3, m1, m2 and n are as described in the claims and description); a raw material for such a substrate; and a method for producing such substrates.Type: GrantFiled: July 9, 2018Date of Patent: May 23, 2023Assignees: NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA, NISSAN CHEMICAL CORPORATIONInventors: Hiromi Kitano, Tadashi Nakaji, Yuki Usui, Taito Nishino, Takahiro Kishioka
-
Publication number: 20230140801Abstract: The invention provides an antibody that specifically binds to a 5? to 3? exonuclease domain of a DNA polymerase, or a fragment thereof. The antibody inhibits the 5? to 3? exonuclease activity of a DNA polymerase, or a fragment thereof.Type: ApplicationFiled: December 10, 2021Publication date: May 4, 2023Applicants: TOYOBO CO., LTD., NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMAInventors: Takafumi YOSHIKANE, Nobuyuki KUROSAWA, Masaharu ISOBE
-
Patent number: 11479537Abstract: A new analgesic has been developed for T-type calcium channels as therapeutic targets. The present invention provides a T-type calcium channel inhibitor which is a compound represented by formula (1): wherein each of R1 and R2 independently represents —H or —OH; R3 represents —OH; R4 represents —OH or —H; R5 represents a straight or branched alkyl or cycloalkyl-alkyl group having one to ten carbon atoms or a straight or branched alkenyl or cycloalkyl-alkenyl group having two to ten carbon atoms, or a pharmaceutically acceptable salt or solvate thereof. The present invention also provides this T-type calcium channel inhibitor, a medicament containing the T-type calcium channel inhibitor, and a therapeutic or prophylactic agent for a disease having an effective T-type calcium channel inhibitory action.Type: GrantFiled: September 21, 2018Date of Patent: October 25, 2022Assignees: KINKI UNIVERSITY, NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA, FUSO PHARMACEUTICAL INDUSTRIES, LTD.Inventors: Atsufumi Kawabata, Fumiko Sekiguchi, Maho Tsubota, Naoki Toyooka, Hiroyuki Nishikawa
-
Patent number: 11268173Abstract: A magnesium alloy containing Al, Sr, Ca, and Mn, with the balance being Mg and inevitable impurities, the magnesium alloy having: a structure having an ?-Mg phase, and a precipitate dispersed in at least one of a grain boundary of the ?-Mg phase and a cell boundary, the precipitate including: at least one phase selected from a group A consisting of an Al2Sr phase, an Al4Sr phase, a (Mg, Al)2Sr phase, and a (Mg, Al)4Sr phase; and at least one phase selected from a group B consisting of an Al2Ca phase and a (Mg, Al)2Ca phase, the magnesium alloy having, in a cross section, a total area rate of a group A precipitate and a group B precipitate of greater than or equal to 2.5% and less than or equal to 30%.Type: GrantFiled: November 15, 2018Date of Patent: March 8, 2022Assignees: Sumitomo Electric Industries, Ltd., National University Corporation University of ToyamaInventors: Manabu Mizutani, Katsuhito Yoshida, Seiji Saikawa
-
Publication number: 20210130788Abstract: Provided are a ligand-bearing substrate which has a surface at least partially coated with a polymer (P3) containing structural units represented by the formulae (1a) and (1b) (in the formulae, R1, R2, X, Y, L, Q1, Q2, Q3, m1, m2 and n are as described in the claims and description); a raw material for such a substrate; and a method for producing such substrates.Type: ApplicationFiled: July 9, 2018Publication date: May 6, 2021Applicants: NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA, NISSAN CHEMICAL CORPORATIONInventors: Hiromi KITANO, Tadashi NAKAJI, Yuki USUI, Taito NISHINO, Takahiro KISHIOKA
-
Publication number: 20210102239Abstract: A method for enabling rapid and accurate determination of the number of bacterial cells in a specimen using a PCR method includes the following steps: (1) a first PCR step of carrying out a PCR method using a nucleic acid derived from a specimen as a template and a universal primer pair for amplifying a bacterial 16S rRNA gene to obtain a first amplification product; (2) a second PCR step of carrying out a nested PCR method using a primer pair(s) for amplifying an internal sequence(s) of the sequence of the first amplification product obtained by the first PCR step to obtain a second amplification product; and (3) a bacterial number determination step of obtaining the number of bacterial cells in the specimen based on the amount of the second amplification product obtained in the second PCR step and using calibration data.Type: ApplicationFiled: June 21, 2018Publication date: April 8, 2021Applicants: MITSUI CHEMICALS, INC., NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMAInventors: Hideki Niimi, Isao Kitajima, Akio MIYAKOSHI, Yoshitsugu HIGASHI
-
Publication number: 20200354819Abstract: A magnesium alloy containing Al, Sr, Ca, and Mn, with the balance being Mg and inevitable impurities, the magnesium alloy having: a structure having an ?-Mg phase, and a precipitate dispersed in at least one of a grain boundary of the ?-Mg phase and a cell boundary, the precipitate including: at least one phase selected from a group A consisting of an Al2Sr phase, an Al4Sr phase, a (Mg, Al)2Sr phase, and a (Mg, Al)4Sr phase; and at least one phase selected from a group B consisting of an Al2Ca phase and a (Mg, Al)2Ca phase, the magnesium alloy having, in a cross section, a total area rate of a group A precipitate and a group B precipitate of greater than or equal to 2.5% and less than or equal to 30%.Type: ApplicationFiled: November 15, 2018Publication date: November 12, 2020Applicants: Sumitomo Electric Industries, Ltd., NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMAInventors: Manabu MIZUTANI, Katsuhito YOSHIDA, Seiji SAIKAWA
-
Patent number: 10660935Abstract: A peptide consisting of an amino acid sequence of GPPGPAG (SEQ ID NO: 1) is disclosed. According to the present invention, a novel compound for improving memory disorder is provided.Type: GrantFiled: August 18, 2017Date of Patent: May 26, 2020Assignees: JAPAN BIO PRODUCTS Co., Ltd., National University Corporation University of ToyamaInventors: Chihiro Tohda, Taiichi Kaku, Hiroyuki Miyazaki
-
Patent number: 10501813Abstract: Disclosed is a thermostable DNA polymerase preparation which can illimitably reduce the risk of false positivity in the detection of a subject microorganism utilizing a gene amplification reaction and therefore enables the selective amplification of DNA for detecting the subject microorganism even when the amount of the subject microorganism is small and therefore the amount of DNA collected therefrom is extremely small, and can be produced at a reduced cost. Also disclosed is a method for quantifying or quantifying/identifying a subject organism to be detected rapidly, conveniently and with high sensitivity using the preparation of the present invention.Type: GrantFiled: August 28, 2017Date of Patent: December 10, 2019Assignees: HOKKAIDO MITSUI CHEMICALS INC., NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMAInventors: Homare Tabata, Hiroshi Minami, Hideki Niimi, Isao Kitajima, Tomohiro Ueno, Shiroh Hayashi, Masashi Mori
-
Publication number: 20190358287Abstract: A peptide consisting of an amino acid sequence of GPPGPAG (SEQ ID NO: 1) is disclosed. According to the present invention, a novel compound for improving memory disorder is provided.Type: ApplicationFiled: August 18, 2017Publication date: November 28, 2019Applicants: JAPAN BIO PRODUCTS Co., Ltd., National University Corporation University of ToyamaInventors: Chihiro TOHDA, Taiichi KAKU, Hiroyuki MIYAZAKI
-
Patent number: 10479836Abstract: The present invention relates to a therapeutic agent for pulmonary hypertension comprising an interleukin-5 receptor (hereinafter, abbreviated to “IL-5R”)-inhibiting compound and therapeutic method therefor. More specifically, the present invention relates to a therapeutic agent for pulmonary hypertension comprising an antibody or an antibody fragment capable of specifically binding to the extracellular region of IL-5R and a therapeutic method therefor.Type: GrantFiled: May 31, 2016Date of Patent: November 19, 2019Assignees: National University Corporation University of Toyama, KYOWA KIRIN CO., LTD.Inventors: Masashi Ikutani, Kiyoshi Takatsu, Hiromi Ehara, Ikuko Fujino, Shinya Ogawa
-
Patent number: 10416165Abstract: A method for separating cells capable of producing target antigen-specific monoclonal antibodies (TASMAs) wherein a cell group including antibody-producing cells is immobilized using a reversible crosslinking agent having cell membrane-permeating properties. The immobilized cell group is subjected to cell membrane dissolution using a surface active agent; and the cell group is reacted with a labeling target antigen. In the stained cell group a that has reacted with the labeling target antigen is separated. A method to produce TASMAs by separating mRNA from the cell separated using the method; preparing cDNA and preparing antigen-specific monoclonal antibodies or fragments thereof from the prepared cDNA. Also provided are a method whereby at least one cell capable of producing TASMAs is separated and a method whereby said antibodies can be produced by using the separated cell.Type: GrantFiled: August 10, 2016Date of Patent: September 17, 2019Assignee: NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMAInventors: Nobuyuki Kurosawa, Masaharu Isobe
-
Publication number: 20180371583Abstract: A magnesium alloy is provided that includes: 5.0 mass % or more and 15.0 mass % or less of Al; 2.5 mass % or more and 7.0 mass % or less of Sr; 0.05 mass % or more and less than 3.0 mass % of Ca; and 0.1 mass % or more and 0.6 mass % or less of Mn, with a remainder including Mg and inevitable impurities.Type: ApplicationFiled: July 13, 2017Publication date: December 27, 2018Applicants: SUMITOMO ELECTRIC INDUSTRIES, LTD., NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMAInventors: Manabu MIZUTANI, Katsuhito YOSHIDA, Nozomu KAWABE, Seiji SAIKAWA
-
Publication number: 20180292407Abstract: A method for separating cells capable of producing target antigen-specific monoclonal antibodies (TASMAs) wherein a cell group including antibody-producing cells is immobilized using a reversible crosslinking agent having cell membrane-permeating properties. The immobilized cell group is subjected to cell membrane dissolution using a surface active agent; and the cell group is reacted with a labeling target antigen. In the stained cell group a that has reacted with the labeling target antigen is separated. A method to produce TASMAs by separating mRNA from the cell separated using the method; preparing cDNA and preparing antigen-specific monoclonal antibodies or fragments thereof from the prepared cDNA. Also provided are a method whereby at least one cell capable of producing TASMAs is separated and a method whereby said antibodies can be produced by using the separated cell.Type: ApplicationFiled: August 10, 2016Publication date: October 11, 2018Applicant: National University Corporation University of ToyamaInventors: Nobuyuki Kurosawa, Masaharu Isobe
-
Patent number: 10023943Abstract: An Al—Mg—Si-based aluminum alloy includes 0.015 to 0.12 mass % of Sr, the aluminum alloy producing a cast metal structure in which Mg2Si is crystallized in a fine agglomerate form.Type: GrantFiled: April 7, 2016Date of Patent: July 17, 2018Assignees: National University Corporation University of Toyama, Ahresty CorporationInventors: Seiji Saikawa, Gen Okazawa, Hiroshige Niwa, Kiyoshi Terayama, Susumu Ikeno, Emi Yanagihara, Shin Orii, Suguru Takeda
-
Patent number: 9907852Abstract: The purpose of the present invention is to provide an anticancer agent for potentiating an antitumor effect, alleviating side effects, and further extending the survival rate by concomitant use with a component having an anticancer effect. An anticancer agent combining arctigenin and a component other than arctigenin that has an anticancer effect, in which the anticancer agent may be a combination drug or may be a kit configured from a formulation containing arctigenin and a formulation containing a component that has an anticancer effect, and the concomitant use of arctigenin and the component having an anticancer effect more strongly inhibits tumor growth and reduces the proportion of cancer stem cells in the tumor, making it possible to extend the total survival time and to alleviate side effects caused by the component having an anticancer effect.Type: GrantFiled: April 10, 2015Date of Patent: March 6, 2018Assignees: National University Corporation University of Toyama, Kracie Pharma, Ltd., National Cancer Center, Tokyo University of Science FoundationInventors: Hiroyasu Esumi, Masafumi Ikeda, Katsuya Tsuchihara, Shigeki Chiba, Satoshi Yomoda, Takanori Kawashima, Toshiki Okubo, Yasuhiro Tezuka, Kenta Murata
-
Publication number: 20180057860Abstract: Disclosed is a thermostable DNA polymerase preparation which can illimitably reduce the risk of false positivity in the detection of a subject microorganism utilizing a gene amplification reaction and therefore enables the selective amplification of DNA for detecting the subject microorganism even when the amount of the subject microorganism is small and therefore the amount of DNA collected therefrom is extremely small, and can be produced at a reduced cost. Also disclosed is a method for quantifying or quantifying/identifying a subject organism to be detected rapidly, conveniently and with high sensitivity using the preparation of the present invention.Type: ApplicationFiled: August 28, 2017Publication date: March 1, 2018Applicants: Hokkaido Mitsui Chemicals Inc., National University Corporation University of ToyamaInventors: Homare Tabata, Hiroshi Minami, Hideki Niimi, Isao Kitajima, Tomohiro Ueno, Shiroh Hayashi, Masashi Mori
-
Patent number: 9700572Abstract: The present invention is intended to provide a novel anticancer agent which is effective to a cancer. After administering an agent prepared using burdock fruit extract to a pancreas cancer patient so that a dose of arctigenin was 100 mg or more per day, the tumor reducing effect was observed, and, in addition, lowering of tumor markers was confirmed. The present invention provides an anticancer agent containing arctigenin, wherein a dose of the arctigenin is 100 mg or more per day. In addition, the present invention provides the anticancer agent containing arctigenin and arctiin at a weight ratio of arctigenin/arctiin=0.7 to 1.3.Type: GrantFiled: September 24, 2014Date of Patent: July 11, 2017Assignees: National Cancer Center, Kracie Pharma, Ltd., National University Corporation University of ToyamaInventors: Hiroyasu Esumi, Masafumi Ikeda, Chika Miyoshi, Shigetoshi Kadota, Toshiki Okubo, Satoshi Yomoda, Takafumi Fuse, Takanori Kawashima, Shigeki Chiba